Spectral Diagnostics (OTCMKTS:EDTXF) Shares Down 4.9% – What’s Next?

Spectral Diagnostics Inc. (OTCMKTS:EDTXF – Get Free Report)’s stock price traded down 4.9% during trading on Thursday. The company traded as low as $0.7770 and last traded at $0.7770. 190 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 10,489 shares. The stock had previously closed at $0.8170.

Spectral Diagnostics Stock Down 4.9%

The business has a 50 day moving average of $0.87 and a 200 day moving average of $0.95. The company has a market capitalization of $228.94 million, a P/E ratio of -7.77 and a beta of 0.14.

About Spectral Diagnostics

(Get Free Report)

Spectral Diagnostics Inc, now known as Spectral Medical Inc, is a Canadian medical-device and biotechnology company focused on the diagnosis and treatment of sepsis and other conditions associated with systemic inflammation. The company’s work centers on identifying endotoxemia, a condition in which bacterial endotoxins enter the bloodstream and contribute to severe immune responses.

Spectral’s principal diagnostic product is the Endotoxin Activity Assay, or EAA, a blood test designed to measure a patient’s endotoxin activity and help clinicians assess the risk of developing severe sepsis.

Further Reading

Receive News & Ratings for Spectral Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.